NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

"It is speculative to conclude that NWBO's decision to hold its annual meeting on December 29, 2025, and to increase authorized shares to 900 million is a sign of a substantial delay by the MHRA. The company has not publicly stated this reason, and there could be other business or financial reasons, such as funding future operations or a planned share offering, for these actions.
Annual Meeting: The date of an annual meeting is set by the company's board and is not necessarily linked to a specific regulatory decision. It may be set to accommodate other business, such as the upcoming 2025 fiscal year-end report or board elections.
Increased Authorized Shares: An increase in authorized shares is often done to provide the company with flexibility to raise capital through a share offering in the future. This could be to fund its operations, research and development, or a future acquisition, and may not be directly tied to the MHRA approval timeline.
Alternative Explanations: These decisions are likely part of a broader financial and strategic plan that could be influenced by a variety of factors, such as upcoming clinical trial results, the need for working capital, or a strategic partnership"